Compare 3M Company (MMM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Merck & Co., Inc. — how do they compare? 3M Company trades at $164.59 (market cap $86.39B), while Merck & Co., Inc. trades at $148.18 (market cap $366.28B). The key difference: Merck & Co., Inc. is far larger — about 4.2× 3M Company's market cap, and Merck & Co., Inc. pays the higher dividend (2.29%). Which is the better fit depends on your goals.
| MMM | MRK | |
|---|---|---|
Market Cap | $86.39B | $366.28B |
Sector | Industrials | Health |
52-Week High | $183.79 | $156.43 |
52-Week Low | $141.10 | $77.60 |
Enterprise Value | $95.61B | $413.04B |
Dividend Yield | 1.86% | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $167.52, down 0.62% on the day, with a bearish technical signal but strong recent earnings beats. The company shows solid profitability with an 11.9% net income margin and 82.77% ROE, though revenue has declined from 2022 peaks. Positive news highlights strength in transportation, electronics, and safety segments, while consumer demand remains soft.
The stock offers a balanced outlook: analyst consensus is a Buy with a $173 price target, but high debt and cost pressures pose risks. Earnings momentum from industrial growth supports upside, yet valuation multiples like a 29.75 P/E suggest limited margin for error. Investors should weigh robust fundamentals against macroeconomic and segment-specific headwinds.
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
